Gilead Sciences Inc. (GILD)
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
GILD Reports Positive Results From Late-Stage Liver Disease Study
Gilead reports positive phase III IDEAL results as Livdelzi boosts ALP normalization in PBC patients, supporting regulatory discussions.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams.
US FDA approves Gilead's drug for deadly liver infection
The U.S. Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver infection that previously had no approved treatment options.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
Gilead Sciences NASDAQ: GILD Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development.
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
